At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 112 enrolled
Drug / intervention
Gardasilbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Open-Label Pilot Trial of the Safety and Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men
In Brief
A Phase 2 clinical trial evaluating Gardasil for Infection and Precancerous Condition. Completed, enrolled 112 participants across 8 sites.
Detailed Summary
RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine therapy works in treating men with HIV-1 infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfection, Precancerous Condition
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), The Emmes Company, LLC
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartNov 2007
Primary CompletionMay 2010
Study CompletionOct 2011
TodayJul 2026
First PostedAug 8, 2007
Enrollment StartNov 1, 2007
Primary CompletionMay 1, 2010
Study CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.9 years ago
Interventions
Gardasilbiological
week 0, 8, 24, 128